If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
147
results.
Updated on
29/04/2026 [07:59:00]
Results 125 to 147 of 147
Absstract of: KR20260030686A
본 발명은 줄기세포에서 뇌유래-신경영양인자 단백질 또는 이를 암호화하는 유전자의 발현을 유도하는 방법, 및 뇌유래-신경영양인자 단백질 또는 이를 암호화하는 유전자를 발현하는, 줄기세포를 유효성분으로 포함하는, 파킨슨병 치료 또는 예방용 약학적 조성물에 관한 것으로, 본 발명에 따르면, 세포치료제 개발에서 가장 큰 난관 중 하나인 이식 세포의 생착률을 효과적으로 향상시킬 수 있다. 일반적으로 세포의 생착은 이식 조직의 미세환경이 어떠한 조건을 갖추고 있는지에 따라 크게 좌우된다. 본 발명은 BDNF를 줄기세포 내에서 발현하도록 함으로써, 이식된 세포의 항염증 기능을 증대시키고 다양한 종류의 신경세포 생존을 강력하게 촉진할 수 있다. 따라서, 본 발명의 기술을 적용한 세포는 이식 후 생착률을 높일 수 있을 뿐만 아니라, BDNF가 신경 축삭(axon)의 발달과 성장에 관여하여 손상된 흑질선조체 경로(nigro-striatal pathway)의 재생을 촉진함으로써 파킨슨병(Parkinson’s disease, PD)의 병증 개선에 기여할 수 있다. 또한, 본 발명은 CRISPR-Cas9 유전자 편집기술을 활용하여 인간 신경능 유래 줄기세포 내에 BDNF 유전자를 안정적으로 knock-in 함으로써, 기존 치료법에 비해 향상된 치료 효과를 기대할 수 있다. 특히, 본 발명에
Absstract of: US20260060947A1
This invention relates to the use of nitroalkene derivatives for the treatment of neurodegenerative conditions in mammals in which neuroinflammation is a contributing factor, such as in amyotrophic lateral sclerosis (ALS).
Absstract of: US20260061034A1
Methods for preventing or treating brain neuronal diseases are provided. The methods include administering mesenchymal stem cells having increased agouti-related peptide (AgRP) expression or a conditioned medium thereof to a subject in need thereof. In some embodiments, the conditioned medium contains AgRP. The methods may further comprise administering ghrelin. The brain neuronal diseases include Alzheimer's disease, frontotemporal dementia, tauopathy, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, stroke, thrombosis, embolism, head trauma, cerebral circulatory or metabolic disorders, brain dysfunction, and dementia.
Absstract of: US20260062389A1
Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
Absstract of: AU2026201203A1
Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimers' disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia/reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and/or animal models of prion disease, PD and ALS. eb e b
Absstract of: US20260062413A1
Provided are compounds that are kinase inhibitors. The compounds have improved properties that lead to specific targeting of kinases without inhibiting the activity of related enzymes, which make them useful for therapeutic intervention in a variety of disorders and disease in which inhibition of the kinase can be clinically useful, e.g., Alzheimer's disease and other neurodegenerative diseases. The compounds can also be used in methods of treating a neurodegenerative disease associated with inflammation, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, epilepsy, stroke, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), or a disease or disorder such as deafness, glaucoma, organ failure, or cancers, including, but not limited to, those susceptible to combination therapy with epigenetic targets such as those associated with bromodomain (BRD) proteins, histone deacetylases (HDACs), and the like.
Absstract of: WO2026050519A2
The present invention provides nucleic acid molecules and methods that use miRNA sequences that knocking down mRNA for the human DNA mismatch repair protein MutS Homolog 3 (MSH3), thereby resulting in the treatment of Huntington's Disease.
Absstract of: WO2026047040A1
The present invention relates to a compound of formula (I) wherein R1 is a hydrogen atom, halogen or -(C1-C2)alkyl, R2 is -halo(C1-C2)alkoxy, and R3 and R4 form together with N to which they are attached an optionally substituted 5-7 membered monocyclic heterocycloalkyl ring or an optionally substituted 8-11 membered bicyclic heterocycloalkyl ring. The present invention also relates to a medicament and a pharmaceutical composition comprising said compound of formula (I), as well as their therapeutic uses, in particular as inhibitor of NOD-like receptor protein 3 inflammasome for preventing and/or treating Parkinson's disease, frontotemporal Dementia, Multiple System Atrophy, Alzheimer's disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis or brain injury.
Absstract of: US20260061011A1
A Bifidobacterium animalis subsp. lactis for reducing Abeta42 deposition and an application, a name of the Bifidobacterium animalis subsp. lactis is Bifidobacterium animalis subsp. lactis IOB-LO7, and classified as Bifidobacterium animalis subsp. lactis, the Bifidobacterium animalis subsp. lactis IOB-LO7 is preserved in the General Microbiology Center of the China General Microbiological Culture Collection Center (CGMCC) on Dec. 23, 2021, with the collection number of CGMCC No. 24185. By reducing the levels of Aβ42 in the cerebral cortex and hippocampus, clearing Aβ amyloid plaques, improving communication between neurons, reducing brain neuroinflammation, and protecting nerve cells, it helps to restore cognitive function and improve Alzheimer's disease. Additionally, it can also improve gut microbiota imbalance caused by Alzheimer's disease.
Absstract of: AU2024345495A1
The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.
Absstract of: AU2024327965A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of a-syn protein depletion (proteinopenia) are provided, including material compositions that retain native function of a-syn protein while limiting and/or preventing amyloid formation and/or aggregation of said protein. Material compositions and formulations for enhancing protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF halflife, and for facilitating peptide/protein synthesis and purification are also provided.
Absstract of: AU2024325238A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Absstract of: US20260062497A1
Provided are pharmaceutical formulations and dosing regimen for antibody-based treatment of amyotrophic lateral sclerosis (ALS).
Absstract of: EP4702978A1
An agent for treating or preventing amyotrophic lateral sclerosis, wherein an active component of the agent essentially consists of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The active component may consist of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: US20260099855A1
0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.
Absstract of: MX2026000096A
The invention relates to liposome-encapsulated apomorphine, processes for preparing said liposome-encapsulated apomorphine and to the use of such in the treatment of Parkinson's disease.
Absstract of: US20260099855A1
0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.
Absstract of: MX2025011198A
Provided herein are compositions and methods for the treatment of neuroinflammatory diseases and conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (AES), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), neuromyelitis optica (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), Vascular dementia (VAD), Anti- myelin oligodendrocyte glycoprotein antibody disease (MOGAD), Transverse myelitis (TM), Autoimmune Encephalitis (AE), Acute disseminated encephalomyelitis (ADEM), Chronic meningitis (CM), Central nervous system (CNS) vasculitis, Hashimoto's encephalitis (HE), Neurosarcoidosis (NS), Multiple system atrophy (MSA), Migraine, Chemotherapy-induced pain or Dementia-related pain.
Absstract of: MX2025014476A
The present invention relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, which has improved stability by reducing the content of related substances of crisdesalazine, and has an increased dissolution rate by improving the intrinsic solubility thereof. The composition of the present invention secures stability and bioavailability, and thus is more effective in treating neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy accompanied by free radical neurotoxicity, cerebral trauma, spinal injury, and the like), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerosis inflammation, and the like), stress disorders (anxiety disorder, depression, and the like), and the like.
Nº publicación: MX2025012556A 02/03/2026
Applicant:
4M THERAPEUTICS INC [US]
Absstract of: MX2025012556A
Novel compositions of N-desmethyl ruboxistaurin L-lactate. The use of compositions of N-desmethyl ruboxistaurin L-lactate to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate in the treatment of subjects having a neurological disease and/or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate administered in combination with lithium or other treatments for bipolar disorder are also disclosed.
BOPI
Electronic site
